A citrus polymethoxyflavonoid, nobiletin, is a novel MEK inhibitor that exhibits antitumor metastasis in human fibrosarcoma HT-1080 cells

Biochemical and Biophysical Research Communications

Volumn 366, Issue 1, 2008, Pages 168-173

  Miyata, Yoshiki ^a   Sato, Takashi ^a   Imada, Keisuke ^a   Dobashi, Akira ^a   Yano, Masamichi ^b   Ito, Akira ^a  

^a TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^b NARO Bio oriented Technology Research Advancement Institution   (Japan)

Author keywords

3,5,6,7,8,3 ,4 Heptamethoxyflavone; Antitumor metastasis; ERK; Flavonoid; Matrix metalloproteinase; MEK; Natsudaidain; Nobiletin

Indexed keywords

3 HYDROXY 5,6,7,8,3',4' HEXAMETHOXYFLAVONE; 3,5,6,7,8,3',4' HEPTAMETHOXYFLAVONE; ANTIMETASTATIC AGENT; FLAVONOID; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MYELIN BASIC PROTEIN; NATSUDAIDAIN; NOBILETIN; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL FREE SYSTEM; CITRUS FRUIT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROSARCOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; METASTASIS INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CITRUS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FIBROSARCOMA; FLAVONES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PLANT EXTRACTS;

CITRUS; CITRUS DEPRESSA;

EID: 37349052385     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2007.11.100     Document Type: Article

References (31)

1. Nichenametla S.N., Taruscio T.G., Barney D.L., and Exon J.H. A review of the effects and mechanisms of polyphenolics in cancer. Crit. Rev. Food Sci. Nutr. 46 (2006) 161-183
2. Li Y., Fang H., and Xu W. Recent advance in the research of flavonoids as anticancer agents. Mini Rev. Med. Chem. 7 (2007) 663-678
3. Singhal R.L., Yeh Y.A., Praja N., Olah E., Sledge Jr. G.W., and Weber G. Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem. Biophys. Res. Commun. 208 (1995) 425-431
4. Shen F., and Weber G. Synergistic action of quercetin and genistein in human ovarian carcinoma cells. Oncol. Res. 9 (1997) 597-602
5. Kang T.B., and Liang N.C. Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells. Biochem. Pharmacol. 54 (1997) 1013-1018
6. Shao Z.M., Wu J., Shen Z.Z., and Barsky S.H. Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res. 58 (1998) 4851-4857
7. Huang Y.T., Hwang J.J., Lee P.P., Ke F.C., Huang J.H., Huang C.J., Kandaswami C., Middleton Jr. E., and Lee M.T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor., Br. J. Pharmacol. 128 (1999) 999-1010
8. Yu M., Bowden E.T., Sitlani J., Sato H., Seiki M., Mueller S.C., and Thompson E.W. Tyrosine phosphorylation mediates Con A-induced membrane type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in MDA-MB-231 human breast carcinoma cells. Cancer Res. 57 (1997) 5028-5032
9. Sato T., Koike L., Miyata Y., Hirata M., Mimaki Y., Sashida Y., Yano M., and Ito A. Inhibition of activated protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinase 1 and 9 in human fibrosarcoma HT-1080 cells. Cancer Res. 62 (2002) 1025-1029
10. Minagawa A., Otani Y., Kubota T., Wada N., Furukawa T., Kumai K., Kameyama K., Okada Y., Fujii M., Yano M., Sato T., Ito A., and Kitajima M. The citrus flavonoid, nobiletin, inhibits peritoneal dissemination of human gastric carcinoma in SCID mice. Jpn. J. Cancer Res. 92 (2001) 1322-1328
11. Ishiwa J., Sato T., Mimaki Y., Sashida Y., Yano M., and Ito A. Citrus flavonoid, nobiletin, suppresses the production and gene expression of matrix metalloproteinase 9/gelatinase B in rabbit synovial fibroblasts. J. Rheumatol. 271 (2000) 20-25
12. Lin N., Sato T., Takayama Y., Mimaki Y., Sashida Y., Yano M., and Ito A. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem. Pharmacol. 65 (2003) 2065-2071
13. Campbell P.M., and Der C.J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 14 (2004) 105-114
14. Viala E., and Pouyssegur J. Regulation of tumor cell motility by ERK mitogen-activated protein kinases. Ann. NY Acad. Sci. 1030 (2004) 208-218
15. Mocsai A., Jakus Z., Vantus T., Berton G., Lowell C.A., and Ligeti E. Kinase pathways in chemoattractant-induced degranulation of neutrophils: the role of p38 mitogen-activated protein kinase activated by Src family kinases. J. Immunol. 164 (2000) 4321-4331
16. Bernhard E.J., Gruber S.B., and Muschel R.J. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 91 (1994) 4293-4297
17. Himelstein B.P., Lee E.J., Sato H., Seiki M., and Muschel R.J. Transcriptional activation of the matrix metalloproteinase-9 gene in an H-ras and v-myc transformed rat embryo cell line. Oncogene 14 (1997) 1995-1998
18. 2-terminal kinase pathway and inhibition of mitogen-activated protein/extracellular signal-regulated kinase 1/2 phosphorylation in antitumor invasive activity induced by the polymethoxy flavonoid, nobiletin. Mol. Cancer Ther. 3 (2004) 839-847
19. Zheng C.F., and Guan K.L. Properties of MEKs, the kinases that phosphorylate and activate the extracellular signal-regulated kinases. J. Biol. Chem. 268 (1993) 23933-23939
20. Gardner A.M., Vaillancourt R.R., Lange-Carter C.A., and Johnson G.L. MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. Mol. Biol. Cell 5 (1994) 193-201
21. Itoigawa M., Takeya K., and Furukawa H. Cardiotonic flavonoids from Citrus plants (Rutaceae). Biol. Pharm. Bull. 17 (1994) 1519-1521
22. Matsuda S., Kosako H., Takenaka K., Moriyama K., Sakai H., Akiyama T., Gotoh Y., and Nishida E. Xenopus MAP kinase activator: identification and function as a key intermediate in the phosphorylation cascade. EMBO J. 11 (1992) 973-982
23. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol. Chem. 386 (2005) 193-205
24. Shields J.M., Pruitt K., McFall A., Shaub A., and Der C.J. Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10 (2000) 147-154
25. Dudley D.T., Pang L., Decker S.J., Bridges A.J., and Saltiel A.R. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc. Natl. Acad. Sci. USA 92 (1995) 7686-7689
26. Park E.R., Eblen S.T., and Catling A.D. MEK1 activation by PAK: a novel mechanism. Cell. Signal. 19 (2007) 1488-1496
27. Wen-Sheng W. Protein kinase C α trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2. Cancer Lett. 239 (2006) 27-35
28. Menard R.E., and Mattingly R.R. Cell surface receptors activate p21-activated kinase 1 via multiple Ras and PI3-kinase-dependent pathways. Cell Signal. 15 (2003) 1099-1109
29. Iwase Y., Takemura Y., Ju-ichi M., Yano M., Ito C., Furukawa H., Mukainaka T., Kuchide M., Tokuda H., and Nishino H. Cancer chemopreventive activity of 3,5,6,7,8,3′,4′-heptamethoxyflavone from the peel of citrus plants. Cancer Lett. 163 (2001) 7-9
30. Ferriola P.C., Cody V., and Middleton Jr. E. Protein kinase C inhibition by plant flavonoids. Kinetic mechanisms and structure-activity relationships. Biochem. Pharmacol. 38 (1989) 1617-1624
31. Sartor L., Pezzato E., Dell'Aica I., Caniato R., Biggin S., and Garbisa S. Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design. Biochem. Pharmacol. 64 (2002) 229-237